Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113165 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 244
- Enrollment target
NCT00113165 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 244 participants.
The verdict
NCT00113165, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 244 participants
- Enrollment target
Study Summary
This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active medication. In this study, LAMICTAL extended-release or placebo tablets will be added to current seizure treatments.
Interventions
- DRUG LAMICTAL extended-release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113165
The ClinicalTrials.gov registry entry for NCT00113165 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LAMICTAL extended-release is the first listed.
NCT00113165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113165 about?
NCT00113165 is a clinical study titled "Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures". This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active m...
What is the current status of trial NCT00113165?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 244 participants. The study started on 2004-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00113165?
The interventions under investigation include: LAMICTAL extended-release (DRUG).
Who is sponsoring clinical trial NCT00113165?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.